Schizophrenia is a mental health condition that affects how you think, feel, and behave. The condition involves psychosis, which makes it hard to tell what is real and what is not. This can lead to symptoms such as delusions (false beliefs), hallucinations (seeing or hearing things that aren’t there), or disorganized thinking and behavior. Some people also experience low motivation, reduced emotions, or social withdrawal.
Schizophrenia varies from person to person and often follows cycles in which symptoms worsen and then improve, known as relapses and remissions. Although schizophrenia does not have a cure, treatment with antipsychotic medicines and supportive therapies can help manage symptoms and reduce the risk of relapse.
One treatment option is Bysanti (milsaperidone). It was approved by the FDA in 2026 for the treatment of schizophrenia in adults. It may also be used to treat other mental health conditions.
This article covers how Bysanti works for schizophrenia and how it was studied for this use. You may also be interested in learning more about Bysanti side effects and Bysanti interactions.
How Does Bysanti Work for Schizophrenia?
Bysanti belongs to a group of medicines called second-generation antipsychotics, also called atypical antipsychotics. The exact way Bysanti works is not fully understood. However, researchers believe its effects are related to how it blocks certain receptors in the brain.
Receptors are structures on brain cells that respond to chemical signals. Bysanti affects receptors that respond to important brain chemicals called dopamine and serotonin. It also affects norepinephrine and histamine receptors. These chemicals help regulate your mood, thoughts, and behavior. Changes in dopamine and serotonin activity are believed to contribute to symptoms of schizophrenia.
By adjusting how these brain signals work, Bysanti may help improve schizophrenia symptoms.
What Is the Difference Between Bysanti and Fanapt?
Bysanti (milsaperidone) and Fanapt (iloperidone) are closely related medicines. Fanapt was first approved in the United States in 2009, while Bysanti was approved in 2026.
After you take Bysanti, the medicine changes back and forth between milsaperidone and iloperidone. This happens because of simple chemical steps your body uses to process the medicine. Because the medicine switches between these two forms, both Bysanti and Fanapt work in very similar ways and have similar side effects.
How Was Bysanti Studied for Schizophrenia?
The FDA’s approval of Bysanti for treating schizophrenia is based on studies of iloperidone (Fanapt). Because iloperidone and milsaperidone rapidly convert into each other in the body, results from iloperidone studies help show how Bysanti treats this condition.
Iloperidone was studied in adults with schizophrenia in two shorter studies and one longer study. The longer-term study, called the REPRIEVE trial, looked at whether continued treatment could help keep symptoms from coming back (relapse prevention).
In the first short-term study, 706 adults were assigned to receive iloperidone, a placebo (a pill with no medicine in it), or a medicine called risperidone for six weeks. In the second short-term study, 604 adults were assigned to receive iloperidone, placebo, or ziprasidone for four weeks. In both studies, participants were randomly assigned to a treatment group, and neither the participants nor the researchers knew which group each person was in during the study.
The longer-term study included 303 adults with schizophrenia who were clinically stable, meaning their symptoms had not changed much for a long time. After a one-week dose titration period and 12 weeks of treatment with iloperidone, participants who remained stable were randomly assigned either to continue iloperidone or switch to placebo. Researchers then monitored how long it took for symptoms to return or worsen (relapse).
In these studies, people had frequent follow-up visits to see how they were doing. Several rating scales were used to measure schizophrenia symptoms, such as:
- Positive and Negative Syndrome Scale (PANSS): A 30-item scale that measures the severity of symptoms such as hallucinations, delusions, and disorganized thinking. Total PANSS scores range from 30 to 210; higher scores indicate more severe symptoms.
- Brief Psychiatric Rating Scale (BPRS): Measures overall psychiatric symptoms such as anxiety, depression, and psychoses on a scale from 1 to 7. Higher scores mean more severe symptoms.
- Clinical Global Impression (CGI) scales: Scores ranging from 1 to 7 show how severe a person’s illness is (CGI-S) and how much it improves with treatment (CGI-I).
People could not join the studies if they had very severe symptoms (a PANSS score above 100), certain serious medical conditions, or recent suicidal behavior.
At the start of the relapse-prevention phase of the REPRIEVE study:
- The participants’ average age was about 38 years.
- About 59% were male, and the rest were female.
- About 50% were White, 26% were Asian, 20% were Black, less than 1% were Pacific Islander, and the rest identified as other races.
- The average PANSS score was about 55, and the average CGI-S score was about 3.
What Are the Benefits of Bysanti for Schizophrenia Based on Studies?
In the short-term studies, researchers measured changes in symptoms using scales such as the PANSS and BPRS. In these studies, participants taking iloperidone showed larger drops in symptom scores than those taking a placebo by the end of treatment.
The long-term REPRIEVE study looked at whether continuing iloperidone could help prevent relapse in people whose symptoms had stabilized. Partway through the study (interim analysis), early results showed that people who continued taking iloperidone were less likely to relapse than those who switched to placebo. About 20% of participants who continued iloperidone experienced a relapse, compared with about 63% of those who switched to placebo.
Researchers also looked at how long it took for symptoms to return. On average, people who switched to placebo relapsed after about 71 days, while people who continued taking iloperidone relapsed after about 139 days.
After the study ended, researchers analyzed all of the data collected during the trial, including additional relapse events that occurred later. The final results confirmed what the earlier analysis had shown: Relapse was less common in people who continued taking iloperidone than in those who switched to placebo.
Together, these results suggest that treatment with iloperidone — and therefore Bysanti — can improve schizophrenia symptoms and help prevent symptoms from returning in adults with schizophrenia.
Keep in mind that your results may differ from study results.
How Fast Does Bysanti Start to Work for Schizophrenia?
After you take a dose of Bysanti, the medicine reaches its highest levels in the blood within about two to six hours. But it usually takes longer than that to see any effects of the medicine on your symptoms.
In the iloperidone studies, schizophrenia symptoms started to improve within about four weeks of starting treatment. But the timeline and results can vary from person to person.
Ask your health care provider if you have questions about what to expect during treatment.
How Is Bysanti Taken for Schizophrenia?
Bysanti is typically taken by mouth twice a day, with or without food. To reduce the risk of dizziness, the dose is usually increased gradually over several days.
For adults with schizophrenia, treatment usually begins with a low dose that is increased during the first week. The typical starting dose is 1 mg twice daily. Your doctor will gradually increase the dose each day until you reach the amount that works safely for you, up to 12 mg twice daily.
The recommended maintenance dosage of Bysanti for schizophrenia is 6-12 mg twice daily.
Some people process medicines differently because of genetic differences in certain enzymes. One of these enzymes is called CYP2D6, which helps break down many medicines in the body, including Bysanti. People who are “CYP2D6 poor metabolizers” break down certain medicines more slowly and may need a lower dose.
Your health care provider may recommend special testing before starting treatment to see whether a lower dose may be safer for you. Dose adjustments may also be needed if you take certain other medicines that affect how Bysanti is broken down in the body.
Tell your health care provider about all of the medicines and supplements you take, any health conditions you have, or any treatments you have received in the past. In many cases, it can be helpful to bring a trusted family member or caregiver along to your appointments to discuss past treatments and conditions with your health care provider.
Is There Any Cost Assistance Available?
Cost assistance programs may be available to help lower the price of Bysanti prescriptions. The drugmaker may also offer financial support programs for eligible patients. If you have questions about the cost of Bysanti, talk to your health care provider, pharmacist, or insurance company. They may help you find available savings programs or other assistance options.
